We would like to thank all the experts who checked the accuracy of this information, and the volunteers who shared their personal experience to help us develop it.
References
- Della Fera AN, et al. 2021. Persistent Human Papillomavirus Infection. Viruses. 13(2):321.
- de Martel C, et al. 2020. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 8(2):e180–e190.
- Preti M, et al. 2020. Risk of HPV-related extra-cervical cancers in women treated for cervical intraepithelial neoplasia. BMC Cancer. 20(1):972.
- Loopik DL, et al. 2020. The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study. Int J Cancer. 47(3):897–900.
- Liu Y, et al. 2019. Current strategies against persistent human papillomavirus infection (Review). Int J Oncol. 55(3):570–584.
- de Martel C, et al. 2017. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 141(4):664–670.
We write our information based on literature searches and expert review. For more information about the references we used, please contact info@jostrust.org.uk